Carnitine in the treatment of depression

• US 20040009926A1
• Filed: 02/07/2003
• Published: 01/15/2004
• Est. Priority Date: 02/07/2002
• Status: Abandoned Application

• Current Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SPA (Alfasigma S.p.A.)
• Original Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SPA (Alfasigma S.p.A.)
• Inventors: Pettegrew, Jay W., Gershon, Samuel
• Application Number:
  US10/359,560
• Publication Number:
  US 20040009926A1
• Time in Patent Office: Days
• US Class Current: 514/23
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

Geriatric depression is treated with L-carnitine or an alkanoyl L-carnitine, desirably acetyl L-carnitine thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents.

Claims

1. A method for treating depression in a subject comprising the administration to a subject suffering from depression an effective, an effective amount of a carnitine selected from L-carnitine or alkanoyl L-carnitine or of a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine and butyryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.

3. The method of claim 1, wherein the pharmacologically acceptable salt is selected from the group consisting of chloride;

bromide;

iodide;

aspartate, acid aspartate;

citrate, acid citrate;

tartrate;

phosphate, acid phosphate;

fumarate, acid fumarate;

glycerophosphate;

glucose phosphate;

lactate;

maleate, acid maleate;

mucate;

orotate;

oxalate;

acid oxalate;

sulphate, acid sulphate;

trichloroacetate;

trifluoroacetate and methane sulphonate.

4. The method according to claim 1, wherein said administration is in the form of a composition comprising said carnitine or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable excipient and/or vehicle.

5. The method according to claim 1, wherein 0.1 to 3 g/day of the carnitine or of an equivalent amount of a pharmaceutically acceptable salt thereof are administered.

6. The method according to claim 1, wherein acetyl L-carnitine is administered as a pharmacologically acceptable salt selected from the group consisting of chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

7. The method of claim 1 wherein the carnitine is administered in the form of a dietary supplement.

8. The method of claim 1, wherein the carnitine is administered orally, parenterally, rectally, sublingually or transdermally, in the form of a medicament.